

## WEST Search History

DATE: Wednesday, January 24, 2007

Hide? Set Name Query

Hit Count

*DB=PGPB; PLUR=YES; OP=ADJ*



L1 (oxopyridin and azaindol).clm.

1

END OF SEARCH HISTORY


10/826,136

\*\*\*\*\* Welcome to STN International \*\*\*\*\*  
\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 08:43:22 ON 24 JAN 2007

=> file reg

=>Uploading C:\Program Files\Stnexp\Queries\10826136.str



chain nodes :

10 11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 15 16 17 18 19 20

chain bonds :

7-11 10-11 11-12 12-13 12-14 14-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 15-16 15-20 16-17 17-18 18-19 19-20

exact/norm bonds :

5-9 8-9 10-11 12-13 12-14 14-16

exact bonds :

4-7 7-8 7-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20

isolated ring systems :

containing 1 : 15 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom

L1 STRUCTURE UPLOADED

=> dis l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam

L2 2 SEA SSS SAM L1

=> s l1 full

L3 45 SEA SSS FUL L1

=> file caplus

=> s l3

L4 3 L3

=> s l4 and pd<may 2003

23671395 PD<MAY 2003

(PD<20030500)

L5 2 L4 AND PD<MAY 2003

=> dis l5 1-2 bib abs hitstr

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1209981 CAPLUS Full-text

DN 145:505426

TI Preparation of 7-azaindoles as phosphodiesterase 4 inhibitors for treating inflammatory skin diseases and proliferative skin diseases

IN Hofgen, Norbert; Egerland, Ute; Kronbach, Thomas; Marx, Degenhard; Szelenyi, Stefan; Kuss, Hildegard; Polymeropoulos, Emmanuel

PA Germany

SO U.S. Pat. Appl. Publ., 15pp., Cont.-in-part of U.S. Ser. No. 399,051.


CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006258700	A1	20061116	US 2006-329400	20060110
	DE 10053275	A1	20020502	DE 2000-10053275	20001027 <--
	WO 2002034747	A1	20020502	WO 2001-EP12376	20011025 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	ZA 2003003236	A	20030731	ZA 2003-3236	20030425
	US 2004106641	A1	20040603	US 2003-399051	20030617
PRAI	DE 2000-10053275	A	20001027		
	US 2000-244342P	P	20001030		
	WO 2001-EP12376	W	20011025		
	US 2003-399051	A2	20030617		
OS	MARPAT 145:505426				
GI					



AB The title azaindoles I [n = 1, 2; R1 = (un)substituted alkyl, alkenyl, benzyl, etc.; R2, R3 = H, (un)substituted alkyl, Ph, pyridyl, triazolyl; NR2R3 = morpholino, thiomorpholino, thiomorpholine S,S-dioxide, 4-methylpiperazino] were prepared for use as PDE-4 inhibitors. Thus, 1-cyclopropylmethyl-7-azaindole-3-carboxylic acid was converted to the acid chloride and treated with 4-aminomethylpyridine to give the amide I [n = 1; R1 = cyclopropylmethyl; R2 = 4-pyridylmethyl; R3 = H] which had an IC50 of 0.710  $\mu$ M/L against PDE 4.


IT 418794-38-4P 418794-40-8P 418794-42-0P  
418794-44-2P 418794-46-4P 418794-47-5P  
418794-55-5P 418794-57-7P 418794-59-9P  
418794-61-3P 418794-63-5P 418794-64-6P  
418794-66-8P 418794-68-0P 418794-70-4P  
418794-71-5P 418794-73-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 7-azaindoles as phosphodiesterase 4 inhibitors for treating inflammatory skin diseases and proliferative skin diseases)


RN 418794-38-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3-methoxyphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)



RN 418794-40-8 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 418794-42-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-44-2 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-chlorophenyl)methyl]-α-oxo-N-4-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 418794-46-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-4-pyridinyl)-α-oxo- (9CI) (CA INDEX NAME)




RN 418794-47-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-methoxyphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-55-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-methylphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-57-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-hydroxyphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-59-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3-hydroxyphenyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)




RN 418794-61-3 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-(cyclopropylmethyl)-N-(3,5-dichloro-4-pyridinyl)-α-oxo- (9CI) (CA INDEX NAME)




RN 418794-63-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-hexyl-α-oxo- (9CI) (CA INDEX NAME)




RN 418794-64-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methylpropyl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-66-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methyl-2-propenyl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)



RN 418794-68-0 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methoxyethyl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)



RN 418794-70-4 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(1-naphthalenylmethyl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)






RN 418794-71-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-  
α-oxo-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 418794-73-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-  
[(3,5-dimethyl-4-isoxazolyl)methyl]-α-oxo- (9CI) (CA INDEX NAME)



DN 136:340669  
 TI Novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors  
 IN Hoefgen, Norbert; Egerland, Ute; Kronbach, Thomas; Marx, Degenhard;  
 Szelenyi, Stefan; Kuss, Hildegard; Polymeropoulos, Emmanuel  
 PA Arzneimittelwerk Dresden GmbH, Germany  
 SO PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002034747	A1	20020502	WO 2001-EP12376	20011025 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
	US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10053275	A1	20020502	DE 2000-10053275	20001027 <--
	CA 2428468	A1	20020502	CA 2001-2428468	20011025 <--
	AU 200221753	A	20020506	AU 2002-21753	20011025 <--
	EP 1330455	A1	20030730	EP 2001-988718	20011025
	EP 1330455	B1	20050803		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EE 200300166	A	20030815	EE 2003-166	20011025
	BR 2001014903	A	20031014	BR 2001-14903	20011025
	HU 200303034	A2	20031229	HU 2003-3034	20011025
	JP 2004512337	T	20040422	JP 2002-537738	20011025
	NZ 525369	A	20040924	NZ 2001-525369	20011025
	AT 301121	T	20050815	AT 2001-988718	20011025
	PT 1330455	T	20051031	PT 2001-988718	20011025
	RU 2268887	C2	20060127	RU 2003-115621	20011025
	ES 2246349	T3	20060216	ES 2001-1988718	20011025
	NO 2003001722	A	20030414	NO 2003-1722	20030414 <--
	BG 107725	A	20040831	BG 2003-107725	20030416
	IN 2003KN00463	A	20041218	IN 2003-KN463	20030416
	ZA 2003003236	A	20030731	ZA 2003-3236	20030425
	HR 2003000427	A1	20030831	HR 2003-427	20030526
	US 2004106641	A1	20040603	US 2003-399051	20030617
	HK 1053839	A1	20051028	HK 2003-106201	20030829
	US 2006258700	A1	20061116	US 2006-329400	20060110
PRAI	DE 2000-10053275	A	20001027		
	US 2000-244342P	P	20001030		
	WO 2001-EP12376	W	20011025		
	US 2003-399051	A2	20030617		
OS	CASREACT 136:340669; MARPAT 136:340669				
GI					



AB 7-Azaindoles I [n = 1, 2; R1 = (un)substituted alkyl, alkenyl; R2, R3 = H, (un)substituted alkyl, Ph, pyridyl, uracilyl, triazolyl; NR2R3 = morpholino, thiomorpholino, thiomorpholine S,S-dioxide, 4-methylpiperazino] were prepared for use as PDE-4 inhibitors. Thus, 1-cyclopropylmethyl-7-azaindole-3-carboxylic acid was converted to the acid chloride and treated with 4-aminomethylpyridine to give the amide which had an IC50 for PDE-4 inhibition of 0.710  $\mu\text{mol./L}$ .


IT 418794-38-4P 418794-40-8P 418794-42-0P  
418794-44-2P 418794-46-4P 418794-47-5P  
418794-55-5P 418794-57-7P 418794-59-9P  
418794-61-3P 418794-63-5P 418794-64-6P  
418794-66-8P 418794-73-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel 7-azaindoles as phosphodiesterase 4 inhibitors)


RN 418794-38-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3-methoxyphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)



RN 418794-40-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




$\ominus$ x HCl

RN 418794-42-0 CAPLUS


10/826,136

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)



RN 418794-44-2 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-chlorophenyl)methyl]- $\alpha$ -oxo-N-4-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 418794-46-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(3,5-dichloro-4-pyridinyl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-47-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-


10/826,136

methoxyphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-55-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-methylphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-57-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-hydroxyphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-59-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3-hydroxyphenyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RN 418794-61-3 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, 1-(cyclopropylmethyl)-N-(3,5-dichloro-4-pyridinyl)-α-oxo- (9CI) (CA INDEX NAME)




RN 418794-63-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-hexyl-α-oxo- (9CI) (CA INDEX NAME)




RN 418794-64-6 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methylpropyl)-α-oxo- (9CI) (CA INDEX NAME)



RN 418794-66-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methyl-2-propenyl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)


RN 418794-73-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]- $\alpha$ -oxo- (9CI) (CA INDEX NAME)

IT 418794-68-0P 418794-70-4P 418794-71-5P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

RN 418794-68-0 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(2-methoxyethyl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)

RN 418794-70-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-(1-naphthalenylmethyl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)



RN 418794-71-5 CAPLUS  
 CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-  
 α-oxo-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 14 not 15


L6 1 L4 NOT L5

=> dis 16 bib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:927204 CAPLUS Full-text  
 DN 141:395538  
 TI Preparation of 7-azaindolylglyoxylamides as phosphodiesterase IV  
 inhibitors.  
 IN Hoefgen, Norbert; Kuss, Hildegard; Olbrich, Matthias; Egerland, Ute;  
 Rundfeldt, Chris; Steinike, Karin; Schindler, Rudolf  
 PA Elbion A.-G., Germany  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004094416	A1	20041104	WO 2004-EP4339	20040423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10318610	A1	20041111	DE 2003-10318610	20030424
US 2004224971	A1	20041111	US 2004-826136	20040416
AU 2004232483	A1	20041104	AU 2004-232483	20040423
CA 2523063	A1	20041104	CA 2004-2523063	20040423
EP 1613627	A1	20060111	EP 2004-729102	20040423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009790	A	20060530	BR 2004-9790	20040423
CN 1805960	A	20060719	CN 2004-80016650	20040423
JP 2006524209	T	20061026	JP 2006-505246	20040423
NO 2005005515	A	20060124	NO 2005-5515	20051122
PRAI DE 2003-10318610	A	20030424		
WO 2004-EP4339	W	20040423		
OS MARPAT 141:395538				
GI				



AB Title compds. [I; A = N, N-oxide group; B = C, N, N-oxide group; R1 = (substituted) alkyl, alkenyl; R2 = H, alkyl; R3, R4 = H, alkyl, OH, SH, NH2, NO2, cyano, SO3H, CO2H, alkoxy, carbonyl, halo, alkoxy, alkylthio, (substituted) Ph, pyridyl, etc.], were prepared Thus, N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-azaindol-3-yl]glyoxylic acid amide in CH2Cl2 was treated dropwise with m-chloroperbenzoic acid in HOAc followed by stirring for 7 days to give 9.4% N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylic acid amide. I inhibited phosphodiesterase 4 with IC50's in the range of 10-10 M to 10-5 M.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
15.85	188.16

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

10/826,136

CA SUBSCRIBER PRICE

-2.34

-2.34

STN INTERNATIONAL LOGOFF AT 08:44:53 ON 24 JAN 2007